RxDoctor Payments DataLook up a doctor →

Michael Slade, MD

Medical Oncology · Saint Louis, MONPI 1144740200

Payments from drug & device makers

$3,842,805in general payments, 2019–2025

Across 96 payments — averaging $40,029 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$3M
  • Menarini Silicon Biosystems, Inc.$360K
  • Bristol Myers Squibb$279K
  • Beone Medicines USA, Inc.$61K
  • AstraZeneca$48K
  • E.r. Squibb & Sons, L.L.C.$37K
  • plus $99K from 10 others

General payments by program year

20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,842,805 in reported general payments places this provider in the 85th percentile of 144 medical oncology providers in Missouri.

See all medical oncology providers in Missouri

Medicare billing

Part B allowed, 2024
$1,071,235
Medicare patients
280
Services billed
40,158

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →